BioSpace Movers & Shakers, Aug. 7
Disc medicine Jonathan Yu has been named senior vice president of corporate strategy and William Savage has been named director of clinical development for Disc Medicine in Cambridge, Massachusetts. Together they will work to build the company’s portfolio and to further develop the pipeline of hepcidin pathway modulators for the treatment of serious haematological diseases towards the clinic. Prior to joining Disc Medicine, he was the co-founder and head of corporate strategy, finance and operations at Qpex Biopharma. He has also held various leadership positions at The Medicines Company, Acceleron Pharma, SR One, and Johnson & Johnson. Prior to joining Disc Medicine, Savage was the Senior Medical Director at Magenta Therapeutics. Prior to Magenta, he was Global Clinical Development Lead in Hematology in Shire / Takeda.
Perkins Coie – Stephen C. Ferruolo joined Perkins Coies Emerging Companies & Venture Capital (ECVC) as a partner in the San Diego office. Ferruolo will focus on the life sciences sector, representing private and public biotech, pharmaceutical, medical device and digital health companies, as well as technology companies, investors and venture capitalists.
Zealand Pharma– Denmark-based Zealand Pharma A / S has appointed Mads Kronborg as Head of Investor Relations and Communication. Kronborg brings with him more than a decade of corporate communications experience from his time at H. Lundbeck A / S, where he was Head of Corporate Communications and previously Manager of Corporate Media Relations. While at H. Lundbeck, Kronborg helped communicate several acquisitions and other company integrations, supported numerous global product launches, and drove corporate communications strategy. He was also instrumental in the company’s quarterly and annual financial communications.
Humane – California-based Humanigen, Inc. has appointed Timothy E. Morris as Chief Operating Officer and Chief Financial Officer. In addition to his CFO duties, Morris will be responsible for manufacturing and supply chain, corporate and business development, investor and public relations, and human resources. Morris most recently served as CFO of Iovance and led the company’s fundraising of over $ 1 billion, including a recently completed second offering of $ 600 million. Morris has served on the Human Board of Directors since 2016. In connection with this appointment, he has resigned from his position as director of the company.
Romaco Holding GmbH – Michael Van den Bossche has been appointed Managing Director of Romaco Innojet. He will share the management of the company with Bastian Kading, who has headed the company since 2018. In this role he will be responsible for sales, laboratory, customer service and product management.
CN Rio – Based in the UK, CN Bio has appointed James Craven as Chief Commercial Officer and Brian Manning as Director of Sales in the United States. Sarah Payne also joined the company as Product Marketing Manager. After completing a $ 9 million financing round in February, the appointments will help advance CN Bio’s sales and business strategy, with an emphasis on developing the company’s US customer base, the company’s key market. Craven joins CN Bio from Brooks Life Sciences, where he established and managed relationships with global pharmaceutical companies as Director of Market Strategy and Commercial Delivery. He held senior positions at TTP Labtech and Tizian Software. Most recently, Manning was Director of Business Development at InSphero. Previously, he held key positions at Pfizer, DiscoverX, GenScript and Cyclofluidic, where he was Vice President of Business Development in North America. Payne previously held senior marketing roles at leading life science companies, most recently SPT Labtech and GE Healthcare.
Akouos – Alan Smith has been named chief technology officer for Akouos in Boston. Prior to Akouos, Smith was executive vice president of technical operations at Bellicum Pharmaceuticals. Previously, he was Vice President of Research and Development and Cell Therapeutics at LifeNet Health and its subsidiary The Institute of Regenerative Medicine. In addition, the company announced that Saira Ramasastry has been appointed to the Board of Directors as Chairman of the Audit Committee and that board member Arthur Tzianabos has been appointed Chairman of the Board of Directors. Ramasastry is the managing partner of Life Sciences Advisory, a company she founded to provide strategic advice and business development solutions to life science companies. Tzianabos is currently the Chief Executive Officer and President of Homology Medicines, Inc. and leads efforts to develop genetic medicines for patients with rare genetic diseases. Prior to that, Tzianabos was with Shire Plc for nine years.
PharmaLex Group – The Germany-based PharmaLex Group has appointed Sébastien Schmitt as Chief Commercial Officer. In this role, he will oversee all aspects of PharmaLex’s commercial activities and ensure that our customers benefit from a truly integrated service offering. After almost a decade at the ProductLife Group, Schmitt joins PharmaLex, where he managed the supply and trade organization.
MeiraGTx Holdings – Robert K. Zeldin has been named Chief Medical Officer of MeriaGTx Holdings plc. Prior to joining MeiraGTx, Zeldin was the CMO of Immunovant. Prior to that, he was CMO of Acceleron Pharma. Previously, he was CMO of Ablynx NV, Belgium. He has also worked at Novartis, Stallergenes SA and Merck.
Arcturus Therapeutics – Lance Kurata has been named Chief Legal Officer of Arcturus Therapeutics in San Diego. Kurata joins Arcturus from Mintz, where he was a partner in the group of companies and a member of the Life Sciences Practice Group.
Valneva SE – Juan Carlos Jaramillo has been appointed CMO of France-based Valneva SE. He will succeed Wolfgang Bender, who will retire at the end of October. Jaramillo has broad international experience, strong expertise in medicine and clinical development, including vaccines, and global market access. He has worked in various pharmaceutical / biotech organizations including GlaxoSmithKline, Grünenthal and Daiichi Sankyo.
Ribometrix – NC Ribometrix has won Barclay “Buck” Phillips as Chief Operating Officer and Chief Financial Officer. In his most recent position, Phillips was CFO and Senior Vice President, Corporate Development at G1 Therapeutics. Prior to G1 Therapeutics, Phillips was Senior Vice President, CFO and Treasurer of Novavax. Previously, he was CFO at Micromet, a company acquired by Amgen in 2012.